Electromed, Inc. (ELMD) - 10-Q Summary
Business Context and Reporting Period
Company: Electromed, Inc.
Reporting Period: Quarterly period ended March 31, 2026 (Fiscal Q3 2026).
Business Overview: Electromed develops, manufactures, and markets High Frequency Chest Wall Oscillation (HFCWO) airway clearance products, primarily the SmartVest System, for homecare and hospital markets in the U.S. and internationally. The company operates as a single reporting segment.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2026 | Nine Months Ended Mar 31, 2026 |
|---|---|---|
| Net Revenues | $18,575,000 | $54,359,000 |
| Gross Profit | $14,643,000 (78.8% margin) | $42,659,000 (78.5% margin) |
| Operating Income | $3,766,000 (20.3% margin) | $10,056,000 (18.5% margin) |
| Net Income | $3,003,000 | $7,900,000 |
| Diluted EPS | $0.35 | $0.91 |
| Cash and Equivalents (Mar 31, 2026) | $16,985,000 | |
| Working Capital | ~$40,002,000 | |
| Debt | $0 outstanding on $10M revolving credit facility |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 18.4% ($2.9M) for the quarter and 16.6% ($7.8M) for the nine-month period compared to the prior year.
- Homecare: Increased 18.6% (quarter) and 16.7% (nine months), driven by higher volume from additional sales representatives and increased productivity.
- Hospital: Increased 42.5% (quarter) and 27.9% (nine months), reflecting increased sales focus and higher capital/disposal demand.
- Profitability: Operating income surged 76.0% for the quarter and 51.9% for the nine-month period, primarily due to revenue growth and improved gross profit margins.
- Expenses: SG&A expenses rose 7.2% (quarter) and 8.9% (nine months), largely due to higher payroll and travel costs associated with sales force expansion. R&D expenses increased 30.3% (quarter) and 42.1% (nine months) due to headcount and consulting for product enhancements.
- Cash Flow: Net cash provided by operating activities was $6.67M for the nine months ended March 31, 2026, a decrease from $7.53M in the prior year period, primarily due to a $3.59M increase in accounts receivable.
Guidance, Outlook, and Risks
- Liquidity: Management believes current working capital (~$40M) and the $10M revolving credit facility (undrawn) are sufficient for the next 12 months. The credit facility matures December 16, 2026.
- Capital Allocation: The company continues a stock repurchase program authorized for up to $10M. As of March 31, 2026, $3.92M has been spent, with approximately $6.08M remaining available.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 impacts R&D deductibility. Electromed anticipates electing to accelerate deductions, estimating a $428,000 reduction in cash taxes paid in 2026.
- Risks: Key risks include reimbursement changes from Medicare/Medicaid/private payers, raw material shortages, regulatory compliance, competition, and the ability to renew the credit facility.
Investor Verification Checklist
- Receivables Quality: Verify the aging of accounts receivable, which increased by $3.6M, and the adequacy of allowances for credit losses given the reliance on third-party payers.
- Reimbursement Stability: Monitor changes in Medicare and private payer coverage policies for HFCWO devices, as this drives the majority of homecare revenue.
- Debt Covenants: Confirm ongoing compliance with the BMO Bank credit facility covenants (max 2.50x funded debt ratio, min 1.20x fixed charge coverage).
- Share Repurchase Impact: Assess the impact of the ongoing $10M buyback program on future liquidity and cash flow availability.
- Product Mix: Track the transition and adoption rates of the newer SmartVest Clearway system versus legacy products to ensure sustained gross margin levels.